Eli Lilly (LLY) Stock Forecast: What Could Drive It in 2026
Short answer
No one can reliably forecast LLY's price, and Walnut does not publish targets. What is useful is the setup. For Eli Lilly, the drivers that could push it higher are real, and so are the risks that could weigh on it. Below is each side plus a framework to form your own view. This is descriptive, not a prediction or a recommendation.
What could drive Eli Lilly (LLY) higher?
1. GLP-1 obesity and diabetes leadership.
Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, has driven rapid revenue growth amid enormous demand for metabolic treatments. Lilly and Novo Nordisk effectively define this category, and the addressable population for obesity and related conditions is very large, giving Lilly a long potential runway if it sustains supply and efficacy leadership.
2. Manufacturing scale-up.
Demand for incretin medicines has outstripped supply, so Lilly is investing billions in new manufacturing capacity. Expanding production is a key lever: it directly unlocks revenue that demand already exists for, and meeting supply better than competitors can translate into durable share in a fast-growing market.
3. Diversified pipeline.
Beyond GLP-1s, Lilly has franchises and candidates across oncology, immunology, and neuroscience, including the Alzheimer's antibody donanemab (Kisunla) and next-generation metabolic compounds such as oral and combination incretins. A deep pipeline reduces reliance on any single product and offers additional growth vectors over time.
What could weigh on LLY?
LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence.
How to think about a LLY forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the LLY guide and whether LLY is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the LLY outlook
The honest bottom line: Eli Lilly (LLY)'s outlook hinges on whether its drivers (above) outpace its risks, and no one can promise which wins. Treat any LLY forecast as a scenario, not a certainty, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around LLY with Walnut
Use Eli Lilly as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Eli Lilly (LLY)?
+
No one can reliably predict where LLY will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Eli Lilly higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive LLY higher?
+
The main growth drivers are GLP-1 obesity and diabetes leadership; Manufacturing scale-up; Diversified pipeline. Whether they play out is the real question, not a guaranteed path.
What are the risks to LLY?
+
LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence.
Will LLY stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Eli Lilly's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is LLY a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the LLY "is it a buy?" page for a framework. Walnut is not an investment adviser.
Why has LLY grown so fast?
+
Lilly's growth has been driven by surging demand for its GLP-1 incretin medicines for diabetes and obesity (Mounjaro and Zepbound). The obesity treatment market is very large, and Lilly and Novo Nordisk lead it, so rapidly rising prescriptions have lifted revenue and the share price.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.